KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Common Equity (2016 - 2026)

AbbVie has reported Common Equity over the past 14 years, most recently at -$3.3 billion for Q4 2025.

  • Quarterly Common Equity fell 197.21% to -$3.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.3 billion through Dec 2025, down 197.21% year-over-year, with the annual reading at -$3.3 billion for FY2025, 197.21% down from the prior year.
  • Common Equity was -$3.3 billion for Q4 2025 at AbbVie, down from -$2.6 billion in the prior quarter.
  • Over five years, Common Equity peaked at $17.3 billion in Q4 2022 and troughed at -$3.3 billion in Q4 2025.
  • The 5-year median for Common Equity is $12.4 billion (2021), against an average of $9.4 billion.
  • Year-over-year, Common Equity soared 285.21% in 2021 and then tumbled 197.21% in 2025.
  • A 5-year view of Common Equity shows it stood at $15.4 billion in 2021, then rose by 11.99% to $17.3 billion in 2022, then tumbled by 39.86% to $10.4 billion in 2023, then crashed by 67.64% to $3.4 billion in 2024, then tumbled by 197.21% to -$3.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Common Equity are -$3.3 billion (Q4 2025), -$2.6 billion (Q3 2025), and -$138.0 million (Q2 2025).